Tomar Manu, Rao Raghavendra Prahlad, Dorairaj Palaniyamma, Koshta Abhishek, Suresh Sowbhagya, Rafiq Mohamed, Kumawat Rajesh, Paramesh Rangesh, V Babu U, Venkatesh K V
Department of Chemical Engineering, Indian Institute of Technology, Bombay Powai Mumbai - 400076 India
The Himalaya Drug Company Makali Bengaluru 562162 India
RSC Adv. 2019 Jun 12;9(32):18578-18588. doi: 10.1039/c9ra01345h. eCollection 2019 Jun 10.
Hydroxycitric acid (HCA), a major active ingredient of extracts, is known to suppress body weight gain and fat synthesis in animals and humans. But the underlying mechanism of HCA action is not fully understood. Clinical study on 100 obese individuals for a period of 3 months was performed followed by a computational study aimed to investigate the effects of HCA treatment on human subjects at anthropometric and plasma lipid profile levels. A detailed hepatic metabolic model was used to incorporate the effect of HCA at the metabolic pathway level. Perturbation analysis of ATP citrate lyase activity in the metabolic pathway was performed to simulate the net effect of HCA. Significant reductions in body weight, triceps, subscapular, and mid axillary measurements as well as in serum triglyceride, cholesterol, HDL and LDL levels were observed following HCA dosage. During the study, half of the subjects experienced a decline in body weight and the remainder experienced an increase in body weight. However, analysis of fat mass with the help of empirical correlations clearly showed significant reduction in the mean values due to HCA dosage in both cases. An extra increase in fat free mass was responsible for offsetting the decrease in fat mass for the subjects who experienced an increase in body weight during the trials. Perturbation analysis showed a net reduction in fatty acid, triglyceride and cholesterol synthesis along with urea cycle fluxes under lipogenetic conditions. Moreover, protein synthesis fluxes increased under these conditions. These results indicate that HCA treatment can reduce body weight gain and fat accumulation in obese subjects along with improving their anthropometric parameters and metabolic state.
羟基柠檬酸(HCA)是提取物的主要活性成分,已知其能抑制动物和人类体重增加及脂肪合成。但HCA作用的潜在机制尚未完全明确。对100名肥胖个体进行了为期3个月的临床研究,随后进行了一项计算研究,旨在从人体测量学和血浆脂质谱水平研究HCA治疗对人体受试者的影响。使用了详细的肝脏代谢模型来纳入HCA在代谢途径水平的作用。对代谢途径中ATP柠檬酸裂解酶活性进行了扰动分析,以模拟HCA的净效应。服用HCA后,观察到体重、肱三头肌、肩胛下和腋窝中部测量值以及血清甘油三酯、胆固醇、高密度脂蛋白和低密度脂蛋白水平显著降低。在研究期间,一半受试者体重下降,其余受试者体重增加。然而,借助经验相关性对脂肪量进行分析清楚地表明,在两种情况下,由于服用HCA,平均值均显著降低。在试验期间体重增加的受试者中,无脂肪量的额外增加抵消了脂肪量的减少。扰动分析表明,在脂肪生成条件下,脂肪酸、甘油三酯和胆固醇合成以及尿素循环通量均有净减少。此外,在这些条件下蛋白质合成通量增加。这些结果表明,HCA治疗可减少肥胖受试者的体重增加和脂肪堆积,同时改善其人体测量参数和代谢状态。